Isofol Medical: Patent portfolio strengthened

Research Note

2018-08-31

11:55

Isofol Medical announced this morning that a patent has been approved in the USA, strengthening the patent protection for arfolitixorin significantly. The patent covers the active pharmaceutical ingredient (API), the drug product and the finalised solution that is administered to patients.

AN

Arvid Necander

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.